Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, Henk M., Plesner, Torben, Laubach, Jacob P., Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C., Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M., Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1506348

Cited by (1,000)

Items 801–900 of 1,000

  1. Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients
    Sabrina Traxel, Linda Schadt, Tatjana Eyer, Vanessa Mordasini, Claudine Gysin, Ludvig A. Munthe, Felix K Niggli, David Nadal, Simone Bürgler · 2018 · Oncogene
  2. Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
    Su-Hee Cho, Ho‐Jin Shin, Ki Sun Jung, Do Young Kim · 2019 · Turkish Journal of Hematology
  3. Evolution or revolution in multiple myeloma therapy and the role of the UK
    Gordon Cook, Curly T. C. M. Morris · 2020 · British Journal of Haematology
  4. A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
    Mariarosaria Sessa, Francesco Cavazzini, Maurizio Cavallari, Gian Matteo Rigolin, Antonio Cuneo · 2020 · Genes
  5. Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study
    Lucio Gordan, Melody M. Chang, Marie‐Hélène Lafeuille, Hela Romdhani, Fuad Paramasivam, Eric M. Maiese, Caroline McKay · 2021 · Drugs - Real World Outcomes
  6. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta‐analysis
    Congcong Cao, Xin Zhou, Qun Ma · 2021 · Pharmacology Research & Perspectives
  7. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials
    Ademola Samuel Ojo, Oluwasegun Austine Akinyemi, Mojisola O. Araoye, Ahmed Said Ali · 2022 · Clinical Lymphoma Myeloma & Leukemia
  8. Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid “L-cyclic inosine 5′-diphosphate ribose”
    Joanna M. Watt, Richard Milton Graeff, MARK P. THOMAS, Barry V. L. Potter · 2017 · Scientific Reports
  9. Plasma Cell Neoplasms
    Nikhil C. Munshi, Sundar Jagannath · 2017 · Elsevier eBooks
  10. The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
    Nico Gagelmann, Nicolaus Kröger · 2020 · Annals of Hematology
  11. Therapy Sequencing Strategies in Multiple Myeloma: Who, What and Why?
    Caitlin L. Costello, Joseph R Mikhael · 2017 · Future Oncology
  12. Incorporating mRNA therapeutics into biological treatments of hematologic malignancies
    Jaromir Hunia, Jaromir Tomasik, Natalia Czerwik, Parmida Sadat Pezeshki, Dominika Nowis · 2025 · Frontiers in Immunology
  13. Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis
    Baojie Wang, Yufeng Chu, Chao Zhang, Shougang Guo · 2025 · Frontiers in Immunology
  14. Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based Treatments
    Kalliopi Keramida, Theodora-Christina Kyriakou, Athos Antoniades, Carlo Gabriele Tocchetti · 2025 · Current Treatment Options in Oncology
  15. Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study
    Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Ei Fujikawa, Hiroshi Yamazaki, Mikihiro Takamoto, Lixia Pei et al. · 2025 · International Journal of Hematology
  16. Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems
    Yu-Qian Tang, Jia-Xing Li, W. Ye, Yiwen Du, Ying Zhang, Yun-Xia Ye, Yu-Ping Gong · 2026 · Journal of Translational Medicine
  17. Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective
    Alberto L. Horenstein, Kristine A. Frerichs, Angelo Corso Faini, Niels W.C.J. van de Donk, Fabio Malavasi · 2026 · Frontiers in Immunology
  18. Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report
    Hong-Yao Xu, Yao‐Kuang Huang, Ling Dong, Hua Yu, Bo Lin · 2024 · Frontiers in Medicine
  19. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
    Julio Delgado, Małgorzata Zienowicz, Paula B. van Hennik, Alexandre Moreau, Christian Gisselbrecht, Harald G. Enzmann, Francesco Pignatti · 2021 · The Oncologist
  20. Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
    Hui Xiong, Fengyan Luo, Pengfei Zhou, Jizu Yi · 2021 · Antibody Therapeutics
  21. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
    Matthew T. Campbell, Amishi Yogesh Shah, Pavlos Msaouel, Nizar M. Tannir, Arlene Odelia Siefker-Radtke, Ashish M. Kamat, Neema Navai, Colin P. Dinney, Priya Rao, Charles Chuanhai Guo et al. · 2024 · Cancer Research Communications
  22. Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
    Wassilis S.C. Bruins, Rosa Rentenaar, John R. Newcomb, Wenrou Zheng, Ruud W. J. Ruiter, Thomas Baardemans, Eric Poma, Chris Moore, Garrett L. Robinson, Anya Lublinsky et al. · 2024 · HemaSphere
  23. Development and Preclinical Validation of a Novel 89Zr-Labeled BCMA-Targeting Antibody for ImmunoPET Imaging: Application in Multiple Myeloma Models and First-In-Nonhuman-Primates
    Tianyao Wang, Qi Yang, Wenpeng Huang, Xinyao Sun, Youlan Lei, Hui Xu, Lele Song, Xiaojiang Duan, Futao Liu, Wenzhi Wang et al. · 2025 · Journal of Medicinal Chemistry
  24. Management of high-risk Myeloma: an evidence-based review of treatment strategies
    Nicola Lehners, Patrick John Hayden, Hartmut Goldschmidt, Marc Steffen Raab · 2016 · Expert Review of Hematology
  25. Future therapeutic options for patients with Waldenström macroglobulinemia
    Jorge Julio Castillo, Zachary R. Hunter, Guang Yang, Kimon V. Argyropoulos, Maria Lia Palomba, Steven Peter Treon · 2016 · Best Practice & Research Clinical Haematology
  26. Should minimal residual disease negativity not be the end point of myeloma therapy?
    Pieter Sonneveld · 2017 · Blood Advances
  27. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort
    Nadjoua Maouche, Anandagopal Srinivasan, Heather Leary, Freya Collings, Bing Tseu, Grant D. Vallance, Karthik Ramasamy, Jaimal Kothari · 2021 · Journal of Oncology Pharmacy Practice
  28. The Role of Nicotinamide Adenine Dinucleotide in the Pathogenesis of Rheumatoid Arthritis: Potential Implications for Treatment
    Weiqian Chen, Caihong Yi, Jin Lin · 2018 · European Medical Journal
  29. Biological research on the occurrence and development of multiple myeloma and its treatment
    Yue Wu, Xiangjun Shi, Xinchen Yao, Xinru Du · 2023 · Immunity Inflammation and Disease
  30. Cellular immunity in the era of modern multiple myeloma therapy
    Zhaoyun Liu, Xianghong Zhao, Hongli Shen, Xiaohan Liu, Xintong Xu, Rong Fu · 2023 · International Journal of Cancer
  31. Supportive Therapy in Multiple Myeloma: Practical Recommendations
    Maksim Valerevich Solovev, М. В. Соловьева, Larisa Pavlovna Mendeleeva · 2023 · Clinical oncohematology
  32. 74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis
    Odise Cenaj, Jayme L. Dahlin, Dulce M. Buencamino, Jacob P. Laubach, Petr Jarolı́m · 2017 · Clinical Biochemistry
  33. Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
    Fumihiko Nakamura, Ryo Nasu · 2019 · Annals of Hematology
  34. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
    Barry A. Paul, Shebli Atrash, Manisha Bhutani, Peter Michael Voorhees, Issam S. Hamadeh, Saad Z. Usmani · 2020 · Expert Review of Hematology
  35. EBV-related lymphoma after long-term daratumumab treatment: a case report
    Ilse P. G. Verpoorte-Botden, Monique C. Minnema, Reinier A P Raymakers · 2020 · Blood Cancer Journal
  36. Monoclonal Antibodies
    Christian Klein · 2018 · MDPI eBooks
  37. Multiple Myeloma
    Mario A. Dicato · 2018 · Springer eBooks
  38. CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab
    Barbara Castella, Roberto Mina, Francesca Gay · 2019 · Cytometry Part A
  39. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements
    Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu · 2025 · Current Treatment Options in Oncology
  40. Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203)
    Sung‐Soo Park, Seo-Young Goo, Young‐Woo Jeon, Seung‐Ah Yahng, Seung‐Hwan Shin, Chang‐Ki Min · 2023 · Journal of Cancer Research and Clinical Oncology
  41. Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma
    Ludovic Saba · 2023 · ONCOLOGY
  42. Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method
    Hana Safić Stanić, Zrinka Kruhonja Galić, Martina Lukić, Jasna Bingulac-Popović, Irena Jukić · 2024 · Transfusion and Apheresis Science
  43. Immunotherapy in Multiple Myeloma
    Charise L. Gleason, Donna Catamero · 2017 · Seminars in Oncology Nursing
  44. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events
    Edmund Watson, Faouzi Djebbari, Alexandros Rampotas, Karthik Ramasamy · 2022 · Expert Review of Hematology
  45. Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
    Alana L. Keller, Daniel W. Sherbenou, Peter A. Forsberg, Tomer Martin Mark · 2022 · Frontiers in Oncology
  46. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Julie Stakiw, Shruthi Ganeshappa Kodad, Richard LeBlanc, Michaël Sébag, Annette E. Hay, Vishal Kukreti, Julie Anne Côté, Fernando Camacho, Molei Fu, Engin Gul et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
  47. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial
    Al-Ola A. Abdallah, Alexander M. Lesokhin, Tomasz Wróbel, Krzysztof Jamroziak, Dominik Dytfeld, Cyrille Touzeau, Attaya Suvannasankha, Xavier P Leleu, Rebecca Wang Silbermann, Abdullah Khan et al. · 2023 · Frontiers in Hematology
  48. Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway
    Xiaotang Di, Yiwen Pan, Jinhua Yan, Jing Liu, Doudou Wen, Hao Jiang, Shubing Zhang · 2023 · Heliyon
  49. Daratumumab in Indian Patients with Relapsed and Refractory Multiple Myeloma: A Prospective, Multicenter, Phase IV Study
    Lalit Kumar, Sameer Ramesh Melinkeri, Prasanth Ganesan, Jeevan Kumar, Ghanashyam Biswas, Nalini Kilara, Harish Pathalingappa, SVSS Prasad, Minish Mahendra Jain, Sourav Kumar Mishra et al. · 2023 · Future Oncology
  50. Refractory Pure Red Blood Cell Aplasia Secondary to Major ABO-Incompatible Allogeneic Stem Cell Transplantation Successfully Treated With Daratumumab
    Clinton Wu, Peter Manchen, Ariela Edelman, Muhammad Husnain, Emmanuel Katsanis, Deborah A. Fuchs, Laura Stephens, Sharad Khurana · 2023 · Journal of Hematology
  51. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
    James R. Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Vincent Boccia, Honghao Yang, Mehdi M. Moezi, Stephen Wong Lim, Gary K. Schwartz, Shahrooz Eshaghian et al. · 2024 · Targeted Oncology
  52. Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
    Marwan A. Alrasheed, Khalid A. Alamer, Mashael Albishi, Abdulrahman A. Alsuhibani, Omar A. Almohammed, Abdulrahman M. Alwhaibi, Abdullah N. Almajed, Jeff Jianfei Guo · 2024 · Pharmaceuticals
  53. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
    Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
  54. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma
    Sebastian Grosicki, Agnieszka Barchnicka · 2016 · Expert Review of Hematology
  55. Infusion von Daratumumab in Kombinationstherapien – Praktische Hinweise für den ambulanten Bereich
    Christof Scheid, Markus Munder, Hans Jürgen Salwender, Monika Martha Engelhardt · 2018 · DMW - Deutsche Medizinische Wochenschrift
  56. Metastatic Multiple Myeloma to the Skin
    Alex C. Holliday, Mohammed I. Khan, Sean E. Mazloom, Rahul N. Chavan, Douglas J. Grider · 2019 · Case Reports in Dermatological Medicine
  57. How I treat a refractory myeloma patient who is not eligible for a clinical trial
    Siyang Leng, Divaya Bhutani, Suzanne Lentzsch · 2019 · Hematology
  58. Anticorps anti-CD38 dans le myélome multiple
    Jérôme Moreaux · 2019 · médecine/sciences
  59. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
    Ajai Chari, Markus Munder, Katja Christina Weisel, Matthew W. Jenner, Ceri Bygrave, Maria Teresa Petrucci, Mario Boccadoro, Michèle Cavo, Niels W.C.J. van de Donk, Mehmet Turgut et al. · 2021 · Advances in Therapy
  60. Retrospective review of accelerated daratumumab administration
    Ashka Patel, Stefanie Clark, Jennifer Espiritu, Tenzin Dechen, Qua Tran · 2021 · Journal of Oncology Pharmacy Practice
  61. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis
    Hamza Hassan, Faiz Anwer, Anum Javaid, Hamza Hashmi · 2021 · Critical Reviews in Oncology/Hematology
  62. Antibody based immunotherapy for multiple myeloma: it’s about time
    Taimur Sher, Morie Abraham Gertz · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
  63. The North American Ants Of The Genus Harpagoxenus Forel, With The Description Of A New Species (Hymenoptera: Formicidae).
    M. R. Smith · 1939 · INFM-OAR (INFN Catania)
  64. Multiple myeloma, immunotherapy and minimal residual disease
    J Kusenda, A. KOVARIKOVA · 2016 · Neoplasma
  65. A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo
    Nao Nishimura, Shinya Endo, Shikiko Ueno, Nina Ueno, Hiro Tatetsu, Shinya Hirata, Hiroyuki Hata, Yoshihiro Komohara, Motohiro Takeya, Hiroaki Mitsuya et al. · 2017 · Biochemical and Biophysical Research Communications
  66. Immunotherapy Strategies Against Multiple Myeloma
    Jing Ma, Qian Li, Zhen Yu, Zeng Cao, Su Liu, Lin Chen, Han Li, Shuang Gao, Tinghui Yan, Yafei Wang et al. · 2017 · Technology in Cancer Research & Treatment
  67. Myélome multiple : des critères diagnostiques et pronostiques renouvelés et de forts espoirs thérapeutiques
    Salomon Manier, Marie de Charette de la Contrie, Julia Hieulle, Adrien Daniel, Thierry T.F. Facon · 2019 · La Presse Médicale
  68. Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma
    С. С. Бессмельцев, E.V. Karyagina, Ekaterina Ilyushkina, Ж. Л. Столыпина, Мифтахова Регина Рифкатовна, Ivan Ivanovich Kostroma, Т. Л. Шелковская · 2020 · Clinical oncohematology
  69. A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma ( AMaRC 01‐16)
    Andrew G Spencer, Anna Kalff, Jake Shortt, Hang Quach, Craig Thomas Wallington-Beddoe, John Reynolds, Patricia Walker, Simon James Harrison, Rosanne D. Dunn, Cameron J. Wellard · 2023 · British Journal of Haematology
  70. Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
    Adrián Macías Alegre, Javier de la Rubia, Anna Maria Sureda, Cristina Encinas Rodríguez, Alexia Suárez, María Jesús Blanchard, Joan Bargay, Paula Rodríguez‐Otero, Andrés Insunza, Luis Palomera et al. · 2020 · HemaSphere
  71. Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?
    Stefania Oliva, Antonio Pierangelo Palumbo · 2016 · Expert Opinion on Drug Safety
  72. Comprehensive analysis of thirteen-gene panel with prognosis value in Multiple Myeloma
    Tingting Zheng, Panpan Chen, Yuanlin Xu, Peijun Jia, Yan Li, Yating Li, Jiaming Cao, Wanxin Li, Yazhe Zhen, Ying Zhang et al. · 2023 · Cancer Biomarkers
  73. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies
    Manan Shah, Firas El Chaer, Dora Y. Ho, Zeinab El Boghdadly · 2024 · Transplant Infectious Disease
  74. Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
    Paula Rodríguez‐Otero, Peter Michael Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas Weston Sborov, Meletios Athanasios Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew G Spencer et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
  75. Advances in NK cell therapy for multiple myeloma
    Na Liu, Yujin Zeng, Ying Wang, Congyue Wang, Nan Li, Jun Xu · 2025 · Best Practice & Research Clinical Haematology
  76. Selection and characterization of aptamers against CD38 for clinical diagnostics
    Di Jiang, Lingling Wang, Hengyi Lin, Xiaoqiu Wu, Mingxin Zhang, Songxiao Xu, Zhenhao Long, Tao Bing · 2025 · Chinese Chemical Letters
  77. CD38-targeted therapy with Daratumumab in clinical lung transplantation: A single-center experience
    Caroline Hillebrand, Giuseppe Maggioni, Sophia Auner, Panja Maria Boehm, Daniela Koren, Z. Kovacs, Štefan Schwarz, Gottfried Fischer, Antonia M. S. Müller, Renate Kain et al. · 2025 · JHLT Open
  78. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies
    Hiroki Goto, Mariko Takano, Yoshioki Shiraishi, Sudjit Luanpitpong · 2025 · World Journal of Clinical Oncology
  79. Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy
    Chi Soo Kang · 2025 · Nuclear Medicine and Molecular Imaging
  80. International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences
    Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumaş, Karen M. K. de Vooght, Jill R. Storry et al. · 2026 · Vox Sanguinis
  81. Metabolic reprogramming of myeloid cells in cancer: from lactate–NAMPT axis to AI-guided therapeutics
    In-Gu Lee, Keehoon Jung · 2026 · Experimental & Molecular Medicine
  82. Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance
    Sreejeta Mondal, Nathan J. Becker, Yang Huo, Pengyue Zhang, Travis S. Johnson, Ola Landgren, David Glen Coffey, Brian A. Walker, Enze Liu · 2026 · Biomedicines
  83. NAD⁺ circuits in aging, tissue repair and fibrosis
    Reza Izadpanah, Jay Rappaport, Eckhard U. Alt · 2026 · Ageing Research Reviews
  84. Quels résultats de l’année 2016 vont avoir un impact sur nos pratiques ? Le point de vue du Comité de rédaction du Bulletin du Cancer
    Stéphane Vignot, Thierry André, Anthony Gonçalvès, Romain Guièze, Nicolas Magné, Daniel H. Orbach, Nicolas Penel, Juliette Thariat, Marie Wislez, Jacques‐Olivier Bay · 2016 · Bulletin du Cancer
  85. Synthesis and Evaluation of Thiazoloquinolinones with Linkers To Enable Targeting of CD38
    Stephen S. Scully, Zachary Minden, Ratul Mukerji, Elizaveta A. Andrianova, James Kaberna, Scott P. Lentini, Carlos Tassa, Zhaolin Wang, Susan C. Low, Kevin A. McDonnell · 2016 · ACS Medicinal Chemistry Letters
  86. Rola daratumumabu w leczeniu chorych na nawrotowego i opornego szpiczaka plazmocytowego
    Aleksander Salomon‐Perzyński, Krzysztof Jamroziak · 2018 · Hematologia
  87. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama, Hiroshi Yamazaki, Shinsuke Iida · 2020 · International Journal of Hematology
  88. Recent Updates on Multiple Myeloma
    Khalid Ahmed Al-Anazi · 2022 · IntechOpen eBooks
  89. Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
    Linchun Xu, Shaoze Lin, Xueyang Xing, Yongzhong Su · 2023 · Therapeutic Advances in Hematology
  90. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
    Irene Zamanillo, Lucia Medina de Alba, Rodrigo Gil, Rosalía de la Puerta, Rafael Alonso, Ana Jiménez Ubieto, María‐Teresa Cedena, María Calbacho, Rosa María Ayala, Joaquín Martínez‐López · 2023 · Life
  91. Advances in the management of myeloma: an update
    Teresa Meenaghan, Amjad Hayat, Geraldine Walpole, Maura Dowling · 2023 · British Journal of Nursing
  92. Myelomatous pleural effusion developing after autologous stem cell transplantation in a patient with multiple myeloma: A rare case
    Müzeyyen Aslaner Ak, Figen Barut · 2022 · Indian Journal of Pathology and Microbiology
  93. Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
    Wendy W. L. Lee, Jing Quan Lim, Tiffany Pooi Ling Tang, Daryl Chen Lung Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng et al. · 2024 · Frontiers in Immunology
  94. CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity
    John Franklin Imbery, Celina Wiik, Julia Heinzelbecker, Jenny K. Jebsen, Mia K Dobbing, Nunzio Bottini, Stephanie M. Stanford, Ludvig A. Munthe, Geir Erland Tjønnfjord, Anders Aune Tveita et al. · 2024 · Molecular Therapy Oncology
  95. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication
    Kashyap Padmaraju, Kaitlin Kelly, Andrzej J. Jakubowiak, Benjamin Avi Derman · 2024 · The Oncologist
  96. An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
    Prashant Kapoor, Nitya Nathwani, Tomáš Jelı́nek, Luděk Pour, Aurore Perrot, Meletios Athanasios Dimopoulos, Shang‐Yi Huang, Ivan Špıčka, Saurabh Chhabra, Eben I. Lichtman et al. · 2024 · European Journal Of Haematology
  97. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
    Daniele Derudas, Sabrina Chiriu · 2024 · Pharmaceuticals
  98. Improving Health Outcomes Through Treatment Sequencing Optimization in Multiple Myeloma: A Simulation Model in Transplant‐Ineligible Patients
    Catarina Geraldes, M. Neves, Rui Bergantim, Catarina Cavalcanti da Silva, F. Leal da Costa · 2024 · Cancer Reports
  99. Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
    Jinqiao Li, Xiaoxia Li, Yueyue Fu, Hongbin Meng, Dan Xu, Wenyi Hou · 2024 · Human Vaccines & Immunotherapeutics
  100. Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes
    Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, Samiyah Akram, Nida Jaffar, Jugalkishor Chauhan, Likhita Reddy Allu, Pulkit Saini, Jamil Nasrallah, Mohamed Abdullahi Omar et al. · 2025 · Human Antibodies